Vitamin D, intermediary metabolism and prostate cancer tumor progression

Frontiers in Physiology

Volumn 5 MAY, Issue , 2014, Pages

  Wang, Wei Lin W ^a   Tenniswood, Martin ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Androgen; miRNA; mRNA; Prostate; Vitamin D; Warburg

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANDROGEN; ANDROGEN RECEPTOR; COLECALCIFEROL; GLUCOSE; LACTIC ACID; MESSENGER RNA; MICRORNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; VITAMIN D; VITAMIN D RECEPTOR; ZINC TRANSPORTER;

AMINO ACID METABOLISM; APOPTOSIS; AR GENE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CELL PROLIFERATION; CITRIC ACID CYCLE; CYP27B1 GENE; ENERGY YIELD; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INTERACTION; GLUCOSE METABOLISM; HUMAN; INTRACELLULAR SIGNALING; LIPID METABOLISM; LNCAP CELL LINE; METABOLISM; OXIDATION; PROSTATE CANCER; REVIEW; TRANSCRIPTION REGULATION; VDR GENE; VITAMIN BLOOD LEVEL;

EID: 84904320028     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00183     Document Type: Review

References (105)

1. Altekruse, S. F., Huang, L., Cucinelli, J. E., McNeel, T. S., Wells, K. M., and Oliver, M. N. (2010). Spatial patterns of localized-stage prostate cancer incidence among white and black men in the southeastern United States, 1999-2001. Cancer Epidemiol. Biomarkers Prev. 19, 1460-1467. doi: 10.1158/1055-9965.EPI-09-1310.
2. Alvarez-Diaz, S., Valle, N., Ferrer-Mayorga, G., Lombardia, L., Herrera, M., Dominguez, O., et al. (2012). MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Hum. Mol. Genet. 21, 2157-2165. doi: 10.1093/hmg/dds031.
3. Barnett, C. M., Nielson, C. M., Shannon, J., Chan, J. M., Shikany, J. M., Bauer, D. C., et al. (2010). Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 21, 1297-1303. doi: 10.1007/s10552-010-9557-y.
4. Beer, T. M., and Myrthue, A. (2006). Calcitriol in the treatment of prostate cancer. Anticancer Res. 26, 2647-2651.
5. Blutt, S. E., Polek, T. C., Stewart, L. V., Kattan, M. W., and Weigel, N. L. (2000). A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 60, 779-782.
6. Chadha, M. K., Tian, L., Mashtare, T., Payne, V., Silliman, C., Levine, E., et al. (2010). Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer 116, 2132-2139. doi: 10.1002/cncr.24973.
7. Chan, J. S., Beer, T. M., Quinn, D. I., Pinski, J. K., Garzotto, M., Sokoloff, M., et al. (2008). A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 102, 1601-1606. doi: 10.1111/j.1464-410X.2008.08017.x.
8. Costello, L. C., and Franklin, R. B. (1991a). Concepts of citrate production and secretion by prostate. 1. metabolic relationships. Prostate 18, 25-46. doi: 10.1002/pros.2990180104.
9. Costello, L. C., and Franklin, R. B. (1991b). Concepts of citrate production and secretion by prostate: 2. hormonal relationships in normal and neoplastic prostate. Prostate 19, 181-205. doi: 10.1002/pros.2990190302.
10. Costello, L. C., and Franklin, R. B. (1993). Testosterone regulates pyruvate dehydrogenase activity of prostate mitochondria. Horm. Metab. Res. 25, 268-270. doi: 10.1055/s-2007-1002094.
11. Currie, E., Schulze, A., Zechner, R., Walther, T. C., and Farese, R. V. Jr. (2013). Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153-161. doi: 10.1016/j.cmet.2013.05.017.
12. Deeb, K. K., Trump, D. L., and Johnson, C. S. (2007). Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 7, 684-700. doi: 10.1038/nrc2196.
13. Diosdado, B., van de Wiel, M. A., Terhaar Sive Droste, J. S., Mongera, S., Postma, C., Meijerink, W. J., et al. (2009). MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br. J. Cancer 101, 707-714. doi: 10.1038/sj.bjc.6605037.
14. Esquenet, M., Swinnen, J. V., Heyns, W., and Verhoeven, G. (1995). Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP. Mol. Cell. Endocrinol. 109, 105-111. doi: 10.1016/0303-7207(95)03490-X.
15. Esquenet, M., Swinnen, J. V., Van Veldhoven, P. P., Denef, C., Heyns, W., and Verhoeven, G. (1997). Retinoids stimulate lipid synthesis and accumulation in LNCaP prostatic adenocarcinoma cells. Mol. Cell. Endocrinol. 136, 37-46. doi: 10.1016/S0303-7207(97)00210-4.
16. Flaig, T. W., Barqawi, A., Miller, G., Kane, M., Zeng, C., Crawford, E. D., et al. (2006). A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 107, 266-274. doi: 10.1002/cncr.21982.
17. Franklin, R. B., Feng, P., Milon, B., Desouki, M. M., Singh, K. K., Kajdacsy-Balla, A., et al. (2005). hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol. Cancer 4, 32. doi: 10.1186/1476-4598-4-32.
18. Franklin, R. B., Juang, H. H., Zou, J., and Costello, L. C. (1995). Regulation of citrate metabolism by androgen in the LNCaP human prostate carcinoma cell line. Endocrine 3, 603-607. doi: 10.1007/BF02953026.
19. Garland, C. F., Gorham, E. D., Mohr, S. B., and Garland, F. C. (2009). Vitamin D for cancer prevention: global perspective. Ann. Epidemiol. 19, 468-483. doi: 10.1016/j.annepidem.2009.03.021.
20. Giangreco, A. A., Vaishnav, A., Wagner, D., Finelli, A., Fleshner, N., Van der, K. T., et al. (2013). Tumor suppressor microRNAs, miR-100 and-125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue. Cancer Prev. Res. (Phila) 6, 483-494. doi: 10.1158/1940-6207.CAPR-12-0253.
21. Giovannucci, E. (2009). Expanding roles of vitamin, D. J. Clin. Endocrinol. Metab. 94, 418-420. doi: 10.1210/jc.2008-2695.
22. Harkonen, P. (1981). Androgenic control of glycolysis, the pentose cycle and pyruvate dehydrogenase in the rat ventral prostate. J. Steroid Biochem. 14, 1075-1084. doi: 10.1016/0022-4731(81)90219-3.
23. Harkonen, P. L., Kostian, M. L., and Santti, R. S. (1982). Indirect androgenic control of citrate accumulation in rat ventral prostate. Arch. Androl. 8, 107-116. doi: 10.3109/01485018208987026.
24. He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., et al. (2005). A microRNA polycistron as a potential human oncogene. Nature 435, 828-833. doi: 10.1038/nature03552.
25. Hofer, C., Laubenbacher, C., Block, T., Breul, J., Hartung, R., and Schwaiger, M. (1999). Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur. Urol. 36, 31-35. doi: 10.1159/000019923.
26. Holt, S. K., Kolb, S., Fu, R., Horst, R., Feng, Z., and Stanford, J. L. (2013). Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol. 37, 666-670. doi: 10.1016/j.canep.2013.07.005.
27. Hsieh, T. Y., Ng, C. Y., Mallouh, C., Tazaki, H., and Wu, J. M. (1996). Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem. Biophys. Res. Commun. 223, 141-146. doi: 10.1006/bbrc.1996.0859.
28. Huang, W. C., Li, X., Liu, J., Lin, J., and Chung, L. W. (2012). Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol. Cancer Res. 10, 133-142. doi: 10.1158/1541-7786.MCR-11-0206.
29. Jadvar, H. (2011). Prostate cancer: PET with 18F-FDG, 18F-or 11C-acetate, and 18F-or 11C-choline. J. Nucl. Med. 52, 81-89. doi: 10.2967/jnumed.110.077941.
30. Jiang, M., Ma, Y., Chen, C., Fu, X., Yang, S., Li, X., et al. (2009). Androgen-responsive gene database: integrated knowledge on androgen-responsive genes. Mol. Endocrinol. 23, 1927-1933. doi: 10.1210/me.2009-0103.
31. Jiao, L., Deng, Z., Xu, C., Yu, Y., Li, Y., Yang, C., et al. (2014). MicroRNA-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence. J. Cell. Physiol. 229, 834-844. doi: 10.1002/jcp.24510.
32. Kang, J., and Samuels, D. C. (2008). The evidence that the DNC (SLC25A19) is not the mitochondrial deoxyribonucleotide carrier. Mitochondrion 8, 103-108. doi: 10.1016/j.mito.2008.01.001.
33. Kittler, R., Zhou, J., Hua, S., Ma, L., Liu, Y., Pendleton, E., et al. (2013). A comprehensive nuclear receptor network for breast cancer cells. Cell Rep. 3, 538-551. doi: 10.1016/j.celrep.2013.01.004.
34. Koochekpour, S., Majumdar, S., Azabdaftari, G., Attwood, K., Scioneaux, R., Subramani, D., et al. (2012). Serum glutamate levels correlate with gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin. Cancer Res. 18, 5888-5901. doi: 10.1158/1078-0432.CCR-12-1308.
35. Krishnan, A. V., Peehl, D. M., and Feldman, D. (2003). Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J. Cell. Biochem. 88, 363-371. doi: 10.1002/jcb.10334.
36. Krishnan, A. V., Shinghal, R., Raghavachari, N., Brooks, J. D., Peehl, D. M., and Feldman, D. (2004). Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 59, 243-251. doi: 10.1002/pros.20006.
37. Lazzaro, G., Agadir, A., Qing, W., Poria, M., Mehta, R. R., Moriarty, R. M., et al. (2000). Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur. J. Cancer 36, 780-786. doi: 10.1016/S0959-8049(00)00016-2.
38. Leman, E. S., Arlotti, J. A., Dhir, R., and Getzenberg, R. H. (2003). Vitamin D and androgen regulation of prostatic growth. J. Cell. Biochem. 90, 138-147. doi: 10.1002/jcb.10605.
39. Lindhurst, M. J., Fiermonte, G., Song, S., Struys, E., De Leonardis, F., Schwartzberg, P. L., et al. (2006). Knockout of Slc25a19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia. Proc. Natl. Acad. Sci. U.S.A. 103, 15927-15932. doi: 10.1073/pnas.0607661103.
40. Liu, R. Y., Diao, C. F., Zhang, Y., Wu, N., Wan, H. Y., Nong, X. Y., et al. (2013). miR-371-5p down-regulates pre mRNA processing factor 4 homolog B (PRPF4B) and facilitates the G1/S transition in human hepatocellular carcinoma cells. Cancer Lett. 335, 351-360. doi: 10.1016/j.canlet.2013.02.045.
41. Lundqvist, J., Norlin, M., and Wikvall, K. (2011). 1alpha,25-Dihydroxyvitamin D3 exerts tissue-specific effects on estrogen and androgen metabolism. Biochim. Biophys. Acta 1811, 263-270. doi: 10.1016/j.bbalip.2011.01.004.
42. Maguire, O., Pollock, C., Martin, P., Owen, A., Smyth, T., Doherty, D., et al. (2012). Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor. Mol. Cell. Endocrinol. 364, 54-64. doi: 10.1016/j.mce.2012.08.007.
43. Marshall, D. T., Savage, S. J., Garrett-Mayer, E., Keane, T. E., Hollis, B. W., Horst, R. L., et al. (2012). Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J. Clin. Endocrinol. Metab. 97, 2315-2324. doi: 10.1210/jc.2012-1451.
44. Massie, C. E., Lynch, A., Ramos-Montoya, A., Boren, J., Stark, R., Fazli, L., et al. (2011). The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 30, 2719-2733. doi: 10.1038/emboj.2011.158.
45. McNeal, J. E. (1968). Regional morphology and pathology of the prostate. Am. J. Clin. Pathol. 49, 347-357.
46. Menendez, J. A., and Lupu, R. (2007). Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763-777. doi: 10.1038/nrc2222.
47. Miller, G. J. (1998). Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev. 17, 353-360. doi: 10.1023/A:1006102124548.
48. Moon, J. S., Jin, W. J., Kwak, J. H., Kim, H. J., Yun, M. J., Kim, J. W., et al. (2011). Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem. J. 433, 225-233. doi: 10.1042/BJ20101104.
49. Mordan-McCombs, S., Brown, T., Wang, W. L., Gaupel, A. C., Welsh, J., and Tenniswood, M. (2010). Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. J. Steroid Biochem. Mol. Biol. 121, 368-371. doi: 10.1016/j.jsbmb.2010.03.062.
50. Murthy, S., Agoulnik, I. U., and Weigel, N. L. (2005). Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate 64, 362-372. doi: 10.1002/pros.20251.
51. Narvaez, C. J., Matthews, D., Broun, E., Chan, M., and Welsh, J. (2009). Lean phenotype and resistance to diet-induced obesity in vitamin D receptor knockout mice correlates with induction of uncoupling protein-1 in white adipose tissue. Endocrinology 150, 651-661. doi: 10.1210/en.2008-1118.
52. Narvaez, C. J., Simmons, K. M., Brunton, J., Salinero, A., Chittur, S. V., and Welsh, J. E. (2013). Induction of STEAP4 correlates with 1,25-dihydroxyvitamin D3 stimulation of adipogenesis in mesenchymal progenitor cells derived from human adipose tissue. J. Cell. Physiol. 228, 2024-2036. doi: 10.1002/jcp.24371.
53. Nimitphong, H., Holick, M. F., Fried, S. K., and Lee, M. J. (2012). 25-hydroxyvitamin D(3) and 1,25-dihydroxyvitamin D(3) promote the differentiation of human subcutaneous preadipocytes. PLoS ONE 7:e52171. doi: 10.1371/journal.pone.0052171.
54. Nimptsch, K., Platz, E. A., Willett, W. C., and Giovannucci, E. (2012). Association between plasma 25-OH vitamin D and testosterone levels in men. Clin. Endocrinol. (Oxf.) 77, 106-112. doi: 10.1111/j.1365-2265.2012.04332.x.
55. O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., and Mendell, J. T. (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839-843. doi: 10.1038/nature03677.
56. Park, S. Y., Cooney, R. V., Wilkens, L. R., Murphy, S. P., Henderson, B. E., and Kolonel, L. N. (2010). Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur. J. Cancer 46, 932-936. doi: 10.1016/j.ejca.2009.12.030.
57. Peehl, D. M., Krishnan, A. V., and Feldman, D. (2003). Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J. Nutr. 133, 2461S-2469S.
58. Pilz, S., Frisch, S., Koertke, H., Kuhn, J., Dreier, J., Obermayer-Pietsch, B., et al. (2011). Effect of vitamin D supplementation on testosterone levels in men. Horm. Metab. Res. 43, 223-225. doi: 10.1055/s-0030-1269854.
59. Poliseno, L., Salmena, L., Riccardi, L., Fornari, A., Song, M. S., Hobbs, R. M., et al. (2010). Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci. Signal. 3, ra29. doi: 10.1126/scisignal.200059.
60. Qian, K., Franklin, R. B., and Costello, L. C. (1993). Testosterone regulates mitochondrial aspartate aminotransferase gene expression and mRNA stability in prostate. J. Steroid Biochem. Mol. Biol. 44, 13-19. doi: 10.1016/0960-0760(93)90146-N.
61. Qiao, S., and Tuohimaa, P. (2004). The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth. Biochem. Biophys. Res. Commun. 319, 358-368. doi: 10.1016/j.bbrc.2004.05.014.
62. Rayalam, S., Della-Fera, M. A., Ambati, S., Yang, J. Y., Park, H. J., and Baile, C. A. (2008). Enhanced effects of 1,25(OH)(2)D(3) plus genistein on adipogenesis and apoptosis in 3T3-L1 adipocytes. Obesity (Silver Spring) 16, 539-546. doi: 10.1038/oby.2007.90.
63. van der, R. H., Coebergh, J. W., and de Vries, E. (2009). Sunlight, vitamin D and the prevention of cancer: a systematic review of epidemiological studies. Eur. J. Cancer Prev. 18, 458-475. doi: 10.1097/CEJ.0b013e32832f9bb1.
64. Rivera-Gonzalez, G. C., Droop, A. P., Rippon, H. J., Tiemann, K., Pellacani, D., Georgopoulos, L. J., et al. (2012). Retinoic acid and androgen receptors combine to achieve tissue specific control of human prostatic transglutaminase expression: a novel regulatory network with broader significance. Nucleic Acids Res. 40, 4825-4840. doi: 10.1093/nar/gks143.
65. Scher, H. I., Jia, X., Chi, K., de Wit, R., Berry, W. R., Albers, P., et al. (2011). Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J. Clin. Oncol. 29, 2191-2198. doi: 10.1200/JCO.2010.32.8815.
66. Schwartz, G. G., and Skinner, H. G. (2007). Vitamin D status and cancer: new insights. Curr. Opin. Clin. Nutr. Metab. Care 10, 6-11. doi: 10.1097/MCO.0b013e328011aa60.
67. Shamseddine, A., Farhat, F. S., Elias, E., Khauli, R. B., Saleh, A., and Bulbul, M. A. (2013). High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study. Urol. Int. 90, 56-61. doi: 10.1159/000343780.
68. Shi, H., Norman, A. W., Okamura, W. H., Sen, A., and Zemel, M. B. (2001). 1alpha,25-Dihydroxyvitamin D3 modulates human adipocyte metabolism via nongenomic action. FASEB J. 15, 2751-2753. doi: 10.1096/fj.01-0584fje.
69. Shi, H., Norman, A. W., Okamura, W. H., Sen, A., and Zemel, M. B. (2002). 1alpha,25-dihydroxyvitamin D3 inhibits uncoupling protein 2 expression in human adipocytes. FASEB J. 16, 1808-1810. doi: 10.1096/fj.02-0255fje.
70. Shim, H., Chun, Y. S., Lewis, B. C., and Dang, C. V. (1998). A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc. Natl. Acad. Sci. U.S.A. 95, 1511-1516. doi: 10.1073/pnas.95.4.1511.
71. Siegel, R., Ma, J., Zou, Z., and Jemal, A. (2014). Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29. doi: 10.3322/caac.21208.
72. Simpson, R. U., Hsu, T., Begley, D. A., Mitchell, B. S., and Alizadeh, B. N. (1987). Transcriptional regulation of the c-myc protooncogene by 1,25-dihydroxyvitamin D3 in HL-60 promyelocytic leukemia cells. J. Biol. Chem. 262, 4104-4108.
73. Soga, T. (2013). Cancer metabolism: key players in metabolic reprogramming. Cancer Sci. 104, 275-281. doi: 10.1111/cas.12085.
74. Srinivas, S., and Feldman, D. (2009). A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res. 29, 3605-3610.
75. Sylvestre, Y., De, G. V., Querido, E., Mukhopadhyay, U. K., Bourdeau, V., Major, F., et al. (2007). An E2F/miR-20a autoregulatory feedback loop. J. Biol. Chem. 282, 2135-2143. doi: 10.1074/jbc.M608939200.
76. Szczyrba, J., Nolte, E., Hart, M., Doll, C., Wach, S., Taubert, H., et al. (2013). Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. Int. J. Cancer 132, 775-784. doi: 10.1002/ijc.27731.
77. Thorne, J., and Campbell, M. J. (2008). The vitamin D receptor in cancer. Proc. Nutr. Soc. 67, 115-127. doi: 10.1017/S0029665108006964.
78. Thorne, J. L., Maguire, O., Doig, C. L., Battaglia, S., Fehr, L., Sucheston, L. E., et al. (2011). Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res. 39, 2045-2056. doi: 10.1093/nar/gkq875.
79. Trompeter, H. I., Abbad, H., Iwaniuk, K. M., Hafner, M., Renwick, N., Tuschl, T., et al. (2011). MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS ONE 6:e16138. doi: 10.1371/journal.pone.0016138.
80. Trump, D. L., Deeb, K. K., and Johnson, C. S. (2010). Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 16, 1-9. doi: 10.1097/PPO.0b013e3181c51ee6.
81. Tseng, M., Breslow, R. A., DeVellis, R. F., and Ziegler, R. G. (2004). Dietary patterns and prostate cancer risk in the national health and nutrition examination survey epidemiological follow-up study cohort. Cancer Epidemiol. Biomarkers Prev. 13, 71-77. doi: 10.1158/1055-9965.EPI-03-0076.
82. Vijayakumar, S., Mehta, R. R., Boerner, P. S., Packianathan, S., and Mehta, R. G. (2005). Clinical trials involving vitamin D analogs in prostate cancer. Cancer J. 11, 362-373. doi: 10.1097/00130404-200509000-00002.
83. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 103, 2257-2261. doi: 10.1073/pnas.0510565103.
84. Wagner, D., Trudel, D., Van der, K. T., Nonn, L., Giangreco, A. A., Li, D., et al. (2013). Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J. Clin. Endocrinol. Metab. 98, 1498-1507. doi: 10.1210/jc.2012-4019.
85. Wang, T. T., Tavera-Mendoza, L. E., Laperriere, D., Libby, E., MacLeod, N. B., Nagai, Y., et al. (2005). Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol. Endocrinol. 19, 2685-2695. doi: 10.1210/me.2005-0106.
86. Wang, W. L., Chatterjee, N., Chittur, S. V., Welsh, J., and Tenniswood, M. P. (2011). Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol. Cancer 10, 58. doi: 10.1186/1476-4598-10-58.
87. Wang, W. L., Welsh, J., and Tenniswood, M. (2013). 1,25-Dihydroxyvitamin D3 modulates lipid metabolism in prostate cancer cells through miRNA mediated regulation of PPARA. J. Steroid Biochem. Mol. Biol. 136, 247-251. doi: 10.1016/j.jsbmb.2012.09.033.
88. Wang, X., Gocek, E., Liu, C. G., and Studzinski, G. P. (2009). MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 8, 736-741. doi: 10.4161/cc.8.5.7870.
89. Warburg, O. (1956). [Origin of cancer cells]. Oncologia 9, 75-83. doi: 10.1159/000223920.
90. Warburg, O., Wind, F., and Negelein, E. (1927). The metabolism of tumors in the body. J. Gen. Physiol. 8, 519-530. doi: 10.1085/jgp.8.6.519.
91. Washington, M. N., and Weigel, N. L. (2010). 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology 151, 1409-1417. doi: 10.1210/en.2009-0991.
92. Wehr, E., Pilz, S., Boehm, B. O., Marz, W., and Obermayer-Pietsch, B. (2010). Association of vitamin D status with serum androgen levels in men. Clin. Endocrinol. (Oxf.) 73, 243-248. doi: 10.1111/j.1365-2265.2009.03777.x.
93. Weigel, N. L. (2007). Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr. Rev. 65, S116-S117. doi: 10.1301/nr.2007.aug.S116-S117.
94. Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X. Y., Pfeiffer, H. K., et al. (2008). Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U.S.A 105, 18782-18787. doi: 10.1073/pnas.0810199105.
95. Wong, K. E., Kong, J., Zhang, W., Szeto, F. L., Ye, H., Deb, D. K., et al. (2011). Targeted expression of human vitamin D receptor in adipocytes decreases energy expenditure and induces obesity in mice. J. Biol. Chem. 286, 33804-33810. doi: 10.1074/jbc.M111.257568.
96. Wu, Z., Huang, X., Huang, X., Zou, Q., and Guo, Y. (2013). The inhibitory role of Mir-29 in growth of breast cancer cells. J. Exp. Clin. Cancer Res. 32, 98. doi: 10.1186/1756-9966-32-98.
97. 2+-dependent mechanism. FASEB J. 12, 1391-1396.
98. Yang, X., Du, W. W., Li, H., Liu, F., Khorshidi, A., Rutnam, Z. J., et al. (2013). Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res. 41, 9688-9704. doi: 10.1093/nar/gkt680.
99. Yin, L., Raum, E., Haug, U., Arndt, V., and Brenner, H. (2009). Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol. 33, 435-445. doi: 10.1016/j.canep.2009.10.014.
100. Yin, Y., Yu, Z., Xia, M., Luo, X., Lu, X., and Ling, W. (2012). Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. Eur. J. Clin. Invest. 42, 1189-1196. doi: 10.1111/j.1365-2362.2012.02706.x.
101. Yu, Y., Wu, A., Zhang, Z., Yan, G., Zhang, F., Zhang, L., et al. (2013). Characterization of the GufA subfamily member SLC39A11/Zip11 as a zinc transporter. J. Nutr. Biochem. 24, 1697-1708. doi: 10.1016/j.jnutbio.2013.02.010.
102. Yu, Z., Wang, C., Wang, M., Li, Z., Casimiro, M. C., Liu, M., et al. (2008). A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J. Cell Biol. 182, 509-517. doi: 10.1083/jcb.200801079.
103. Zhao, X. Y., Ly, L. H., Peehl, D. M., and Feldman, D. (1999). Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140, 1205-1212. doi: 10.1210/endo.140.3.6561.
104. Zhou, A. D., Diao, L. T., Xu, H., Xiao, Z. D., Li, J. H., Zhou, H., et al. (2012). beta-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/beta-catenin-signaling pathway. Oncogene 31, 2968-2978. doi: 10.1038/onc.2011.461.
105. Zirath, H., Frenzel, A., Oliynyk, G., Segerstrom, L., Westermark, U. K., Larsson, K., et al. (2013). MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc. Natl. Acad. Sci. U.S.A. 110, 10258-10263. doi: 10.1073/pnas.1222404110.